

Kolkata, India, February 16, 2012

TCG Lifesciences Announces Nomination of Pre-clinical Development Candidate

TCG Lifesciences Limited ("TCGLS") announced today the nomination of a pre-clinical development candidate ("Candidate") under a R&D collaboration entered into in 2009 with Pfizer Inc. ("Pfizer"). As per the agreement, Pfizer will own the Candidate and other back up candidates while TCGLS will receive a milestone payment for its success in moving these molecules to the candidate stage.

The Candidate is a small molecule new chemical entity that meets all the success criteria set by Pfizer, including potency, pharmacokinetics, animal pharmacology, toxicology and related parameters. TCGLS' participation encompasses synthetic chemistry, in-vitro pharmacology, DMPK, in-vivo pharmacology, and preliminary safety.



"This achievement reflects TCGLS' in-depth expertise and ability to work in partnerships. We are delighted to meet our commitment of delivering the Candidate in less than two years time." said Dr. Sourav Basu, AVP, TCG Lifesciences Limited. Mr. Swapan Bhattacharya, Managing Director, TCG Lifesciences Limited, remarked "We have established an excellent track record in our long term collaboration with Pfizer and this candidate nomination is a key milestone of the success of this partnership. This success also demonstrates the progress made by TCGLS in supporting innovation. I sincerely acknowledge the dedication of both the Pfizer and TCGLS scientific teams and congratulate them for this achievement".

Contact TCG Lifesciences:

Corporate Affairs Department

TCG Lifesciences Limited

Mobile: +91 9810730653, email: sandeep.gupta@tcgls.com

About TCG Lifesciences Limited

TCG Lifesciences Limited is a leading Contract Research Services, clinical research, and laboratory informatics company with operations in India, Europe, Japan, Australia and the United States. It is part of The Chatterjee Group, a global investment conglomerate headquartered in New York. TCGLS collaborates to service the multi-disciplinary research efforts of global pharmaceutical and biotechnology companies through its three units: Chembiotek (Discovery Research), Clininvent (Clinical Research Solutions), and LabVantage (Enterprise Informatics). It has trust based relationships with a majority of the global pharmaceutical companies. The relationships span from specific solutions and sourcing services to integrated projects across multiple domains to complete translational research programs in the drug discovery and development space. Learn more at www.tcgls.com/